Alzheimer Disease
Conditions
Brief summary
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Detailed description
The proposed project will enroll a total of 614 women. Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only. Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Interventions
DRUG18-F-Flortaucipir
Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Sponsors
National Institute on Aging (NIA)
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Mayo Clinic Rochester- Inclusion Criteria: * Women who previously participated in this study * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent
Exclusion criteria
* Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion Criteria: * African American Women * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 18F-Flortaucipir PET imaging | 1 day | Cortical 18F-Flortaucipir PET imaging measured once in each participant |
| Pittsburgh compound-B PET imaging | 1 day | Global cortical SUVR measured once in each participant |
Countries
United States
Contacts
Primary ContactJune Kendall-Thomas, CRC
Backup ContactDesirae Howe-Clayton, CRC
Outcome results
None listed